Regeneron

FDA Action Alert: Regeneron, Sanofi, Celgene
FDA Action Alert: Regeneron, Sanofi, Celgene
BioSpace
FDA
drug approvals
Acer Therapeutics
Edsivo
Regeneron
Sanofi
Dupixent
Celgene
Revlimid
Alexion
Soliris
Dova Pharmaceuticals
Doptelet
Nabriva Therapeutics
Contepo
Retrophin
Thiola
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Merck
Keytruda
Melinta Therapeutics
Amag Pharmaceuticals
Palatin
Acer Therapeutics
Sanofi
Regeneron
Alexion
Pfizer
Roche
Navidea Biopharmaceuticals
Ascendis Pharma
Scholar Rock
Adaptive Biotechnologies
BridgeBio
IPOs
G Medical Innovations
Karuna
Morphic Therapeutics
Flag link:
Rivals’ disappointing results in asthma trial drag down shares of Anaptys Bio
Rivals’ disappointing results in asthma trial drag down shares of Anaptys Bio
Stat
Sanofi
Regeneron
IL-33
asthma
monoclonal antibodies
REGN3500
AnaptysBio
Dupixent
Flag link:
Will The Introduction Of A Third Potent Cholesterol Lowering Drug Expand or Shrink The Market?
Will The Introduction Of A Third Potent Cholesterol Lowering Drug Expand or Shrink The Market?
Forbes
The Medicines Company
Amgen
Sanofi
Regeneron
inclisiran
PCSK9 inhibitors
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Yahoo/Benzinga
ADA
Merck
Keytruda
NGM Biopharmaceuticals
NGM313/MK-3655
Corbus Pharmaceuticals
Nektar
Galapagos
Kezar Life Sciences
Kura Oncology
Bluebird Bio
BeiGene
Global Blood Therapeutics
Blueprint Medicines
Regeneron
Arqule
Sunesis
Sutro BioPharma
Incyte
Geron
Forty Seven
Flag link:
ASCO Soundbites, vol. 3: Real-time approvals, Pfizer's second rodeo and 'the busiest ASCO ever'
ASCO Soundbites, vol. 3: Real-time approvals, Pfizer's second rodeo and 'the busiest ASCO ever'
Fierce Pharma
ASCO 2019
Merck
Keytruda
FDA
Pfizer
AstraZeneca
Regeneron
Libtayo
Venclexta
Gazyva
Flag link:
Mark Your Calendar For These June PDUFA Dates
Mark Your Calendar For These June PDUFA Dates
Yahoo/Benzinga
FDA
Merck
Zerbaxa
XERIS
Gvoke HypoPen
Keytruda
Amag Pharmaceuticals
Palatin
Vyleesi
Acer Therapeutics
Edsivo
Sanofi
Regeneron
Dupixent
Alexion
Soliris
Retrophin
Thiola
Allergan
Botox
Flag link:
Go or no go? Merck, Regeneron and Alexion await US expansion
Go or no go? Merck, Regeneron and Alexion await US expansion
EP Vantage
Merck
Keytruda
Sanofi
Regeneron
Dupixent
Alexion
Soliris
FDA
Dova Pharmaceuticals
Retrophin
Flag link:
FDA approves Regeneron’s Eylea for diabetic retinopathy
FDA approves Regeneron’s Eylea for diabetic retinopathy
Pharmaforum
Regeneron
Eylea
diabetic retinopathy
FDA
Bayer
Flag link:
Regeneron’s star bispecific is linked to 2 deaths in a small study — which was no help for its Q1 call
Regeneron’s star bispecific is linked to 2 deaths in a small study — which was no help for its Q1 call
Endpoints
Regeneron
REGN1979
bispecific antibodies
Flag link:
Regeneron bags Calixar tech to support antibody discovery effort
Regeneron bags Calixar tech to support antibody discovery effort
Fierce Biotech
Regeneron
Calixar
antibodies
antibody discovery
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Regeneron
Sanofi
Praluent
FDA
Heron Therapeutics
HTX-011
Nabiva
Orchard Therapeutics
Akari Therapeutics
Aldeyra Therapeutics
BioTime
Audentes Therapeutics
Adaptimmune
GW Pharma
Ionis
Biogen
Ovid Therapeutics
TransMedics
IPOs
Trevi Therapeutics
Flag link:
Praluent's lower list price isn't yielding better sales yet
Praluent's lower list price isn't yielding better sales yet
Biopharma Dive
Sanofi
Regeneron
Praluent
drug pricing
Flag link:
U.S. FDA approves expanded label for Regeneron/Sanofi's cholesterol drug
U.S. FDA approves expanded label for Regeneron/Sanofi's cholesterol drug
Yahoo/Reuters
Regeneron
Sanofi
Praluent
MACE
FDA
Flag link:
Safety setback for Pfizer, Lilly pain drug should have Regeneron and Teva feeling nervous
Safety setback for Pfizer, Lilly pain drug should have Regeneron and Teva feeling nervous
Biopharma Dive
Pfizer
Eli Lilly
painkillers
tanezumab
Regeneron
Teva Pharmaceutical
fasinumab
Flag link:
Regeneron, Alnylam spell out a research alliance that could run beyond a decade, with billions built in for success
Regeneron, Alnylam spell out a research alliance that could run beyond a decade, with billions built in for success
Endpoints
Regeneron
Alnylam
R&D
Flag link:
Alnylam Gets $800M From Regeneron to Bring RNAi to Eye, Brain Diseases
Alnylam Gets $800M From Regeneron to Bring RNAi to Eye, Brain Diseases
Xconomy
Alnylam
Regeneron
RNAi
eye health
brain diseases
Flag link:
FDA approves Dupixent for atopic dermatitis in adolescents
FDA approves Dupixent for atopic dermatitis in adolescents
BioCentury
Dupixent
Regeneron
Sanofi
FDA
atopic dermatitis
Flag link:
Sanofi/Regeneron’s Dupixent shows more promise in nasal polyps
Sanofi/Regeneron’s Dupixent shows more promise in nasal polyps
Pharmaforum
Sanofi
Regeneron
Dupixent
clinical trials
nasal polyps
Flag link:
Regeneron touts one-year diabetic retinopathy data for Eylea
Regeneron touts one-year diabetic retinopathy data for Eylea
Drug Delivery Business News
Regeneron
Eylea
proliferative diabetic retinopathy
Flag link:

Pages